Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
1694
¥ million (interim operating income)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter (interim period) of the fiscal year ending March 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥45,503 million-0.7%
Operating profit¥1,694 million
Ordinary income¥2,923 million
Net income¥5,191 million-33.3%
Selling, general and administrative expenses¥20,015 million
Full-year earnings forecast
Net Sales
¥89,000 million
Operating profit
¥2,500 million
Ordinary income
¥4,400 million
Net income
¥10,000 million
What the company explained in this material
New initiatives
- Initiated a domestic Phase II clinical trial of Cretostimogene grenadenorepvec (CG0070) in September 2026
- Filed a domestic marketing approval application for olutasidenib and licensed development and commercialization rights in Taiwan
Key KPIsA metric the company considers important as a management benchmark.
- Beova revenue¥11,456 millionYear on year against the same period last year+12.1%
- Korsuva revenue¥5,017 millionYear on year against the same period last year+32.3%
- Tavalis revenue¥2,305 millionYear on year against the same period last year+39.8%
- Tavneos revenue¥3,140 millionYear on year against the same period last year-44.0%
- Iselty revenue¥259 million
Segment results
- Pharmaceuticals BusinessNet Sales37,401Year on year against the same period last year-2.5%
- Information Services BusinessNet Sales6,517Year on year against the same period last year+27.7%
- Construction and Facility MaintenanceNet Sales1,067Year on year against the same period last year-42.9%
- Product Sales BusinessNet Sales517Year on year against the same period last year+1.0%
Number of employees
Number of Employees1,843 people
Change during the periodUp 13 from the end of the same period last year
Capital expenditures
¥1,943 million
Annual Dividend
170 yen
Interim Dividend105
Year-end dividend65
Payout ratio
69.1 %
Total payout ratio130.2
Acquisition of treasury shares
¥6,000 million
Number of shares acquired1,300
Share unitthousand shares
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter (interim period) of the fiscal year ending March 2027 |
| Net Sales | ¥45,503 million (YoY -0.7%) |
| Operating profit | ¥1,694 million |
| Ordinary income | ¥2,923 million |
| Net income | ¥5,191 million (YoY -33.3%) |
| Selling, general and administrative expenses | ¥20,015 million |
| Full-year earnings forecast | Net Sales ¥89,000 million / Operating profit ¥2,500 million / Ordinary income ¥4,400 million / Net income ¥10,000 million |
| Segment results | Segment Pharmaceuticals Business / Net Sales ¥37,401 million / Year on year against the same period last year ¥-2.5 million, Segment Information Services Business / Net Sales ¥6,517 million / Year on year against the same period last year ¥27.7 million, Segment Construction and Facility Maintenance / Net Sales ¥1,067 million / Year on year against the same period last year ¥-42.9 million, Segment Product Sales Business / Net Sales ¥517 million / Year on year against the same period last year ¥1 million |
| Key KPIs | Indicator name Beova revenue / Value ¥11,456 million / Year on year against the same period last year ¥12.1 million, Indicator name Korsuva revenue / Value ¥5,017 million / Year on year against the same period last year ¥32.3 million, Indicator name Tavalis revenue / Value ¥2,305 million / Year on year against the same period last year ¥39.8 million, Indicator name Tavneos revenue / Value ¥3,140 million / Year on year against the same period last year ¥-44 million, Indicator name Iselty revenue / Value ¥259 million / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 1,843 people / Change during the period Up 13 from the end of the same period last year |
| Annual Dividend | 170 yen |
| Payout ratio | 69.1 % |
| Acquisition of treasury shares | Amount ¥6,000 million / Number of shares acquired ¥1,300 million / Share unit thousand shares |
| Capital expenditures | ¥1,943 million |
| New initiatives | Initiated a domestic Phase II clinical trial of Cretostimogene grenadenorepvec (CG0070) in September 2026, Filed a domestic marketing approval application for olutasidenib and licensed development and commercialization rights in Taiwan |
Items this document does not state (15)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales decreased due to lower sales of Tavneos, a decline in overseas licensing revenue, and the postponement of construction projects in the construction and facility maintenance business. Meanwhile, Beova, Korsuva, Tavalisse and Iselti grew, while the information services business posted higher sales on increased orders. Operating income and ordinary income turned profitable, mainly due to the year-on-year decrease in research and development expenses related to technology introduction recorded in the previous fiscal year. Interim net income declined because special losses were recorded on Tavneos-related inventories and long-term prepaid expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.